About PhosImmune
PhosImmune is a Healthcare company based in Charlottesville (United States) founded in 2012, and was acquired by Agenusbio in December 2015. Developer of therapeutics cancer vaccines. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
PhosImmune was a clinical-stage biotechnology company developing therapeutic cancer vaccines. The company controls a library of cancer neoantigens discovered by researchers at the University of Virginia. As of Dec 2015, PhosImmune was acquired by Agenus.
- Headquarters Charlottesville, United States
- Stage Acquired
- SectorsHealthcare
- Website phosimmune.com
- Acquired by Agenusbio (Dec 2015)
Funding Insights of PhosImmune
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of PhosImmune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2014 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in PhosImmune
PhosImmune has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Agenusbio and Center for Innovative Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage VC firm funding companies in the US | cit.org | Herndon, United States | ||
Developer of immunotherapies to treat cancer | 1994 | agenusbio.com | Lexington, United States |
Investor details for PhosImmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of PhosImmune
3 dated milestones of PhosImmune across 3 years, from founding to its latest funding, stage changes and deals.
- Founded PhosImmune is founded.
- Funding First funding round.
- Exit Acquired by Agenusbio.
Competitors of PhosImmune
PhosImmune has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of PhosImmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as PhosImmune (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phosimmune
Complete news archive for PhosImmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PhosImmune
PhosImmune was founded in 2012 and raised its 1st funding round 2 years after it was founded.
PhosImmune is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
PhosImmune was a clinical-stage biotechnology company developing therapeutic cancer vaccines. The company controls a library of cancer neoantigens discovered by researchers at the University of Virginia. As of Dec 2015, PhosImmune was acquired by Agenus.
PhosImmune's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
PhosImmune has 2 investors. Key investors include Agenusbio, and Center for Innovative Technology.
Yes. PhosImmune was acquired by Agenusbio in December 2015.